Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice